Markets

News Details

( 30/11/2017 15:37)
Cipla gets WHO nod to sell TB preventing drug in HIV patients

Cipla said it has received approval from the World Health Organisation (WHO) for Q-TIB, a combination drug indicated to help prevent tuberculosis infection in people living with HIV, reported PTI.

Q-TIB is a novel fixed dose combination in a single tablet and it is for the first time that such a combination has been made available in the world.

The company will market the product globally, Cipla said in a statement.

Q-TIB will help prevent tuberculosis infection in people living with HIV as they face a challenged immune system and are prone to infections, which constitute the major source of premature deaths among them.

As per WHO's Global TB Report, 2016, about one million people died of AIDS-related illness. Most of them succumbed to infections, and among them, 4 lakh died of tuberculosis.

ATTENTION INVESTORS "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case

SEBI Regn. NSE: INB231280430 I F&O: INF231280430 I BSE: INB011280436 I NSE CD: INE231280430 I MCX-SX: INE261280430

Copyright © 2017 Rikhav Securities Ltd. All rights reserved

Designed , Developed & Content Powered by DION